New HIV drugs drive Gilead Sciences 3rd-qtr growth
US biotech Gilead Sciences (Nasdaq: GILD) late yesterday reported strong third-quarter 2013 financial results that were driven by the company's HIV/AIDS franchise, notably its newer products.
Total revenues for the quarter increased 15% to $2.78 billion, beating the $2.72 billion forecast of analysts polled by FactSet. Product sales increased 15% to $2.71 billion.
Net income leapt 16.7% to $788.6 million, or $0.47 per diluted share compared to $675.5 million, or $0.43 per diluted share for the third quarter of 2012. Non-GAAP net income for the reporting quarter, which excludes acquisition-related, restructuring and stock-based compensation expenses, rose 11.4% to $879.1 million, or $0.52 per diluted share, beating the $0.48 consensus predicted by analysts, according to Thomson Reuters I/B/E/S..
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze